Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Gross Margin (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Gross Margin for 4 consecutive years, with 93.71% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 209651.0% to 93.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 92.56% through Dec 2025, up 502.0% year-over-year, with the annual reading at 92.56% for FY2025, 120.0% up from the prior year.
  • Gross Margin hit 93.71% in Q4 2025 for Axsome Therapeutics, up from 93.03% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 93.71% in Q4 2025 to a low of 2002.8% in Q4 2024.
  • Historically, Gross Margin has averaged 48.68% across 4 years, with a median of 90.76% in 2024.
  • Biggest five-year swings in Gross Margin: crashed -209249bps in 2024 and later surged 209651bps in 2025.
  • Year by year, Gross Margin stood at 90.6% in 2022, then fell by -1bps to 89.69% in 2023, then crashed by -2333bps to 2002.8% in 2024, then skyrocketed by 105bps to 93.71% in 2025.
  • Business Quant data shows Gross Margin for AXSM at 93.71% in Q4 2025, 93.03% in Q3 2025, and 91.04% in Q2 2025.